Koon Yew Yin's Blog

Why WHO chooses Malaysia to run trials on new drug to fight Covid-19? Koon Yew Yin

Koon Yew Yin
Publish date: Sun, 29 Mar 2020, 11:03 AM
Koon Yew Yin
0 1,417
An official blog in i3investor to publish sharing by Mr. Koon Yew Yin.

All materials published here are prepared by Mr. Koon Yew Yin

The reason why WHO chooses Malaysia is because we have one of the best and cheapest medical treatment in the world. If you don’t believe me, you can examine the comparative costs shown at the end of this article.

I have a cousin who went to UK for studies and did not return. She continued to live in London. A few years ago, she had a lump in her breast and her doctor told her to see a specialist. She had to wait more than a month to see a specialist under the NHS. She preferred to pay more to see a specialist in private hospital.

PETALING JAYA: Malaysia has been chosen by the World Health Organisation (WHO) as one of the countries to run trials on the effectiveness of a drug called Remdesevir to treat Covid-19 patients, says the National Security Council (NSC).

NSC said that Malaysia was chosen due to the ability of the Health ministry to undertake the research.

Health Director-General Datuk Dr Noor Hisham Abdullah (pic) said that the Health Ministry will treat Covid-19 patients with the new drug Remdesevir and will monitor all side effects and its effectiveness.

In a Facebook post, Dr Noor Hisham explained that on Friday (March 27) WHO announced a large global trial, called Solidarity, to find out whether any drugs can treat infections with the new coronavirus.

"It’s an unprecedented effort—an all-out, coordinated push to collect robust scientific data rapidly during a pandemic.

"The study, which could include many thousands of patients in dozens of countries, has been designed to be as simple as possible so that even hospitals overwhelmed by an onslaught of COVID-19 patients can participate.

"WHO is focusing on what it says are the four most promising therapies: an experimental antiviral compound called remdesivir; the malaria medications chloroquine and hydroxychloroquine; a combination of two HIV drugs, lopinavir and ritonavir; and that same combination plus interferon-beta, an immune system messenger that can help cripple viruses," Dr Noor Hisham posted.

The reason why WHO chooses Malaysia is because we have one of the best and cheapest medical treatment in the world. If you don’t believe me, you can examine the figures as shown below.  

 

Heart bypass surgery cost an average of $75,345 in the United States, compared with $15,742 in the Netherlands and $16,492 in Argentina. The average cost of an MRI ranged from $138 in Switzerland to $1,145 in the United States

 

 

More articles on Koon Yew Yin's Blog
Sendai is under priced - Koon Yew Yin

Created by Koon Yew Yin | May 13, 2024

Eversendai Corporation Berhad recently reported its earnings results for the fourth quarter ended December 31, 2023. Here are the key financial highlights:

Eversendai Corporation made a remarkable comeback in FY2023 - Koon Yew Yin

Created by Koon Yew Yin | May 06, 2024

Eversendai Corporation Berhad made a remarkable comeback in FY2023, reporting strong profit growth. Here are the key highlights from their financial performance:

Sendai is still up trend - Koon Yew Yin

Created by Koon Yew Yin | Apr 30, 2024

As shown on the chart below, Sendai has been dropping in the last few days. Today all shareholders must be wondering to sell, hold on or to buy some at a cheaper price.

Eversendai Corporation made a remarkable comeback in FY2023 - Koon Yew Yin

Created by Koon Yew Yin | Apr 22, 2024

Eversendai Corporation Berhad made a remarkable comeback in FY2023, reporting strong profit growth. Here are the key highlights from their financial performance:

Sendai price trend reversal - Koon Yew Yin

Created by Koon Yew Yin | Apr 22, 2024

Sendai price chart below is showing its price trend reversal. It is hitting a record high.

How can KSL double its profit? - Koon Yew Yin

Created by Koon Yew Yin | Apr 18, 2024

After the stock closed yesterday, KSL announced its 4th quarter EPS which is 40.76 sen and its net tangible asset (NTA) backing of Rm 3.65. Its profit increased by 230% more than last year.

Why Sabah will leave Malaysia - Koon Yew Yin

Created by Koon Yew Yin | Mar 29, 2024

Currently Sabah Government does not know that solar panel produces the cheapest electricity???

Malaysia can be one of the richest nations in the world - Koon Yew Yin

Created by Koon Yew Yin | Mar 23, 2024

During my life time I saw every Prime Minister being replaced by another politician for one reason or another. Dr Mahathir managed to stay the longest time of 22 years.

Property Developers comparison - Koon Yew Yin

Created by Koon Yew Yin | Mar 04, 2024

All property developers have just announced their annual profit for 2023. All of them reported increased profit.

My contribution as an Engineer - Koon Yew Yin

Created by Koon Yew Yin | Mar 04, 2024

Although my writing of this article sounds boastful but I feel that it is important to keep this record for posterity. Engineers play a pivotal role in shaping our modern world.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment